Evogene Ltd. (NYSE: EVGN) reported Q3 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $3.31 million versus the consensus estimate of $3.5 million.

As of September 30, 2015, Evogene had $106.4 million in cash, short-term bank deposits and marketable securities, representing a net cash usage of $9.9 million for the nine months ended September 30, 2015.

For earnings history and earnings-related data on Evogene Ltd. (EVGN) click here.